Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment

A Magnan, A Bourdin, C M Prazma, F C Albers, R G Price, S W Yancey, H Ortega, A Magnan, A Bourdin, C M Prazma, F C Albers, R G Price, S W Yancey, H Ortega

Abstract

Background: We performed post hoc analyses to evaluate the effect of humanized monoclonal antibody mepolizumab in patients with severe eosinophilic asthma previously treated with omalizumab.

Methods: Data were collected from two randomized double-blind, placebo-controlled studies: MENSA (NCT01691521: 32-week treatment phase) and SIRIUS (NCT01691508: 24-week treatment phase). Active treatment was 75 mg intravenous mepolizumab (MENSA) or 100 mg subcutaneous mepolizumab (MENSA, SIRIUS). Patients had evidence of eosinophilic inflammation ≥150 cells/μl (at screening) or ≥300 cells/μl (during the previous year). Primary outcomes were the rate of exacerbations (MENSA) and the percentage reduction in oral corticosteroid (OCS) dose (SIRIUS). Other outcomes included lung function (forced expiratory volume in 1 s and morning peak expiratory flow), Asthma Control Questionnaire (ACQ-5), St George's Respiratory Questionnaire (SGRQ) scores, and safety.

Results: Overall, 576 patients were included from MENSA and 135 from SIRIUS, with 13% and 33% previously receiving omalizumab, respectively. In MENSA, mepolizumab reduced the rate of exacerbations by 57% (prior omalizumab) and 47% (no prior omalizumab) vs placebo. In SIRIUS, reductions in OCS use were comparable regardless of prior omalizumab use. Despite reducing chronic OCS use, mepolizumab also resulted in similar reductions in exacerbation rate relative to placebo in both subgroups. Asthma control and quality of life improved with mepolizumab vs placebo in both studies independent of prior omalizumab use, as shown by ACQ-5 and SGRQ scores. Adverse events were also comparable irrespective of prior omalizumab use.

Conclusions: These post hoc analyses indicate that patients with severe eosinophilic asthma respond positively to mepolizumab regardless of prior use of omalizumab.

Keywords: mepolizumab; omalizumab; severe eosinophilic asthma.

© 2016 The Authors. Allergy Published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Annual exacerbation rate by prior omalizumab use in the (A) MENSA and (B) SIRIUS studies (intent‐to‐treat population).

References

    1. Global Initiative for Asthma (GINA) . Global Strategy for Asthma Management and Prevention 2015. Available from: .
    1. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA et al. Can guideline‐defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 2004;170:836–844.
    1. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343–373.
    1. Gibson GP, Simpson LJ. European Network for Understanding Mechanisms of Severe Asthma. The ENFUMOSA cross‐sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003;22:470–477.
    1. Heaney LG, Brightling CE, Menzies‐Gow A, Stevenson M, Niven RM; British Thoracic Society Difficult Asthma Network . Refractory asthma in the UK: cross‐sectional findings from a UK multicentre registry. Thorax 2010;65:787–794.
    1. Moore WC, Bleecker ER, Curran‐Everett D, Erzurum SC, Ameredes BT, Bacharier L et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007;119:405–413.
    1. Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN et al. Acute and chronic systemic corticosteroid‐related complications in patients with severe asthma. J Allergy Clin Immunol 2015;136:1488–1495.
    1. Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23–43.
    1. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006;368:804–813.
    1. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012;18:716–725.
    1. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A et al. T‐helper type 2‐driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009;180:388–395.
    1. Busse W, Corren J, Lanier BQ, McAlary M, Fowler‐Taylor A, Cioppa GD et al. Omalizumab, anti‐IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184–190.
    1. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti‐IgE antibody, in patients with allergic asthma. Chest 2004;125:1378–1386.
    1. Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes‐Rivera I, Zhu J et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011;154:573–582.
    1. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J et al. Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309–316.
    1. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH et al. Randomized trial of omalizumab (anti‐IgE) for asthma in inner‐city children. N Engl J Med 2011;364:1005–1015.
    1. Xolair® Summary of Product Characteristics. Available from: .
    1. Samitas K, Rådinger M, Bossios A. Current update on eosinophilic lung diseases and anti‐IL‐5 treatment. Recent Pat Anti‐infect Drug Discov 2011;6:189–205.
    1. Walsh GM. An update on emerging drugs for asthma. Expert Opin Emerg Drugs 2012;17:37–42.
    1. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW et al. Oral glucocorticoid‐sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371:1189–1197.
    1. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973–984.
    1. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double‐blind, placebo‐controlled trial. Lancet 2012;380:651–659.
    1. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E et al. Mepolizumab for prednisone‐dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985–993.
    1. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198–1207.
    1. Douwes J, Gibson P, Pekkanen J, Pearce N. Non‐eosinophilic asthma: importance and possible mechanisms. Thorax 2002;57:643–648.
    1. Pearce N, Pekkanen J, Beasley R. How much asthma is really attributable to atopy? Thorax 1999;54:268–272.
    1. Ortega H, Katz L, Gunsoy N, Keene O, Yancey S. Blood eosinophil counts predict treatment response in patients with severe eosinophilic asthma. J Allergy Clin Immunol 2015;136:825–826.
    1. Keene ON, Jones MR, Lane PW, Anderson J. Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study. Pharm Stat 2007;6:89–97.
    1. SAS Institute Inc . SAS® 9.3 system options: reference, 2nd edn Cary, NC, USA: SAS Institute Inc.; 2011.
    1. Dullaers M, De Bruyne R, Ramadani F, Gould HJ, Gevaert P, Lambrecht BN. The who, where, and when of IgE in allergic airway disease. J Allergy Clin Immunol 2012;129:635–645.
    1. Kouro T, Takatsu K. IL‐5‐ and eosinophil‐mediated inflammation: from discovery to therapy. Int Immunol 2009;21:1303–1309.
    1. Bousquet J, Siergiejko Z, Swiebocka E, Humbert M, Rabe KF, Smith N et al. Persistency of response to omalizumab therapy in severe allergic (IgE‐mediated) asthma. Allergy 2011;66:671–678.
    1. Ortega H, Miller DP, Li H. Characterization of asthma exacerbations in primary care using cluster analysis. J Asthma 2012;49:158–169.
    1. Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013;187:804–811.
    1. Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007;101:1483–1492.
    1. Wahn U, Martin C, Freeman P, Blogg M, Jimenez P. Relationship between pretreatment specific IgE and the response to omalizumab therapy. Allergy 2009;64:1780–1787.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit